pCR of 37 percent for topical imiquimod in lentigo maligna

pCR of 37 percent for topical imiquimod in lentigo maligna
(HealthDay)—For patients with lentigo maligna (LM) in-situ melanoma, topical imiquimod has a pathological complete regression (pCR) rate of 37 percent, according to a study published online Oct. 6 in the British Journal of Dermatology.

Jeremy R. Marsden, M.D., from the University Hospital Birmingham NHS Foundation Trust in the United Kingdom, and colleagues estimated pCR for LM following imiquimod in a single-arm phase II trial. Data were included for 60 imiquimod applications over 12 weeks for LM, then radical resection.

The researchers found that the pCR rate was 37 percent (10/27). Twelve of 28 patients had clinical complete remission plus negative biopsies, of whom seven out of 11 had pCR on subsequent surgery. The median dose intensity was 86.7 percent. If the cure rate for imiquimod was 80 percent, eight of 16 surveyed patients preferred primary imiquimod over surgery compared with four of 16 patients if the cure rate was ≤50 percent.

"The pCR rate was insufficient to justify phase III investigation of imiquimod versus surgery. Clinical complete response and negative targeted biopsies left uncertainty regarding pathological clearance," the authors write. "Some patients would trade less aggressive treatment of LM against efficacy."


Explore further

Cryotherapy plus imiquimod active in cutaneous melanoma mets

More information: Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: pCR of 37 percent for topical imiquimod in lentigo maligna (2016, October 21) retrieved 18 January 2019 from https://medicalxpress.com/news/2016-10-pcr-percent-topical-imiquimod-lentigo.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more